Ranked by number of R&D employees in 2022
Published September 11,2023. Sources: interviews with representatives of biotech firms below and BIV research. Other firms may have ranked but did not respond to information requests by deadline.
| Rank '23 | Company | Top local executive(s) | Areas of research | Ownership | Year founded | No. staff globally '22/'21 | No. B.C. staff '22/'21 | No. R&D staff '22/'21 |
|---|---|---|---|---|---|---|---|---|
|
1
|
AbCellera |
Carl Hansen, CEO and president |
AbCellera searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease |
Public |
2012 |
495 |
418 |
305 (1) |
|
2
|
STEMCELL Technologies Inc |
Allen Eaves, president and CEO |
Provides cell culture media, cell separation tools and accessory reagents for cell biology research, including stem cell biology, regenerative medicine, immunology and cancer research |
Privately held |
1993 |
1,867 |
1,411 |
290 |
|
3
|
Kardium Inc |
Doug Goertzen, president and COO, Kevin Chaplin, CEO |
Cardiovascular |
Privately held |
2007 |
242 |
236 |
250 |
|
4
|
Zymeworks Inc |
Kenneth Galbraith, chair, president and CEO, Neil Klompas, president and COO (2), Chris Astle, senior vice-president and CFO |
Antibody and protein therapeutics development with a primary focus in oncology |
NYSE:ZYME |
2003 |
NA |
171 |
123 (3) |
|
5
|
Xenon Pharmaceuticals Inc |
Ian Mortimer, president and CEO |
Epilepsy, major depressive disorder |
Public |
1996 |
213 |
153 |
107 |
Want access to the full list and database?
Upgrade to a paid subscription.
To get unlimited access to all of our online features, upgrade today.